Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis

Huanyu Dou, Kevin Birusingh, Jill Faraci, Santhi Gorantla, Larisa Y Poluektova, Sanjay B. Maggirwar, Stephen Dewhurst, Harris A. Gelbard, Howard Eliot Gendelman

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

Human immunodeficiency virus-1 (HIV-1) infection of the nervous system can result in neuroinflammatory events leading first to neuronal dysfunction then to cognitive and behavioral impairments in infected people. The multifaceted nature of the disease process, commonly called HIV-1-associated dementia (HAD), provides a number of adjunctive therapeutic opportunities. One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promote neurite outgrowth and increase β-catenin through inhibiting glycogen synthase kinase 3β activity and tau phosphorylation. We now show that VPA treatment of rat cortical neurons exposed to HIV-1 gp120 prevents resultant neurotoxic activities. This includes the induction of significant neurite outgrowth and microtubule-associated protein 2 (MAP-2) and neuron-specific nuclear protein (NeuN) antigens in affected neuronal cell bodies and processes. Similarly, VPA protects severe combined immunodeficient (SCID) mice against the neurodegeneration of HIV-1ADA infected monocyte-derived macrophages (MDMs). In SCID mice with HIV-1 MDM-induced encephalitis, VPA treatment significantly reduced neuronal phosphorylated β-catenin and tau without affecting HIV-1 replication or glial activation. We conclude that VPA protects neurons against HIV-1 infected MDM neurotoxicity, possibly through its effects on the phosphorylation of tau and β-catenin. The use of VPA as an adjuvant in treatment of human HAD is being pursued.

Original languageEnglish (US)
Pages (from-to)9162-9170
Number of pages9
JournalJournal of Neuroscience
Volume23
Issue number27
StatePublished - Oct 8 2003

Fingerprint

Valproic Acid
Encephalitis
HIV-1
Catenins
SCID Mice
Macrophages
Neurons
Dementia
Phosphorylation
Glycogen Synthase Kinase 3
Nuclear Antigens
Microtubule-Associated Proteins
Virus Diseases
Virus Replication
Nuclear Proteins
Neuroglia
Anticonvulsants
Nervous System
HIV
Therapeutics

Keywords

  • HIV-1 associated dementia
  • HIV-1 encephalitis
  • Monocyte-derived macrophages
  • Neuroprotection
  • Severe combined immunodeficient mice
  • Sodium valproate

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. / Dou, Huanyu; Birusingh, Kevin; Faraci, Jill; Gorantla, Santhi; Poluektova, Larisa Y; Maggirwar, Sanjay B.; Dewhurst, Stephen; Gelbard, Harris A.; Gendelman, Howard Eliot.

In: Journal of Neuroscience, Vol. 23, No. 27, 08.10.2003, p. 9162-9170.

Research output: Contribution to journalArticle

Dou, Huanyu ; Birusingh, Kevin ; Faraci, Jill ; Gorantla, Santhi ; Poluektova, Larisa Y ; Maggirwar, Sanjay B. ; Dewhurst, Stephen ; Gelbard, Harris A. ; Gendelman, Howard Eliot. / Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis. In: Journal of Neuroscience. 2003 ; Vol. 23, No. 27. pp. 9162-9170.
@article{5a6312432db4463e9059f7e718650f9d,
title = "Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis",
abstract = "Human immunodeficiency virus-1 (HIV-1) infection of the nervous system can result in neuroinflammatory events leading first to neuronal dysfunction then to cognitive and behavioral impairments in infected people. The multifaceted nature of the disease process, commonly called HIV-1-associated dementia (HAD), provides a number of adjunctive therapeutic opportunities. One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promote neurite outgrowth and increase β-catenin through inhibiting glycogen synthase kinase 3β activity and tau phosphorylation. We now show that VPA treatment of rat cortical neurons exposed to HIV-1 gp120 prevents resultant neurotoxic activities. This includes the induction of significant neurite outgrowth and microtubule-associated protein 2 (MAP-2) and neuron-specific nuclear protein (NeuN) antigens in affected neuronal cell bodies and processes. Similarly, VPA protects severe combined immunodeficient (SCID) mice against the neurodegeneration of HIV-1ADA infected monocyte-derived macrophages (MDMs). In SCID mice with HIV-1 MDM-induced encephalitis, VPA treatment significantly reduced neuronal phosphorylated β-catenin and tau without affecting HIV-1 replication or glial activation. We conclude that VPA protects neurons against HIV-1 infected MDM neurotoxicity, possibly through its effects on the phosphorylation of tau and β-catenin. The use of VPA as an adjuvant in treatment of human HAD is being pursued.",
keywords = "HIV-1 associated dementia, HIV-1 encephalitis, Monocyte-derived macrophages, Neuroprotection, Severe combined immunodeficient mice, Sodium valproate",
author = "Huanyu Dou and Kevin Birusingh and Jill Faraci and Santhi Gorantla and Poluektova, {Larisa Y} and Maggirwar, {Sanjay B.} and Stephen Dewhurst and Gelbard, {Harris A.} and Gendelman, {Howard Eliot}",
year = "2003",
month = "10",
day = "8",
language = "English (US)",
volume = "23",
pages = "9162--9170",
journal = "Journal of Neuroscience",
issn = "0270-6474",
publisher = "Society for Neuroscience",
number = "27",

}

TY - JOUR

T1 - Neuroprotective activities of sodium valproate in a murine model of human immunodeficiency virus-1 encephalitis

AU - Dou, Huanyu

AU - Birusingh, Kevin

AU - Faraci, Jill

AU - Gorantla, Santhi

AU - Poluektova, Larisa Y

AU - Maggirwar, Sanjay B.

AU - Dewhurst, Stephen

AU - Gelbard, Harris A.

AU - Gendelman, Howard Eliot

PY - 2003/10/8

Y1 - 2003/10/8

N2 - Human immunodeficiency virus-1 (HIV-1) infection of the nervous system can result in neuroinflammatory events leading first to neuronal dysfunction then to cognitive and behavioral impairments in infected people. The multifaceted nature of the disease process, commonly called HIV-1-associated dementia (HAD), provides a number of adjunctive therapeutic opportunities. One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promote neurite outgrowth and increase β-catenin through inhibiting glycogen synthase kinase 3β activity and tau phosphorylation. We now show that VPA treatment of rat cortical neurons exposed to HIV-1 gp120 prevents resultant neurotoxic activities. This includes the induction of significant neurite outgrowth and microtubule-associated protein 2 (MAP-2) and neuron-specific nuclear protein (NeuN) antigens in affected neuronal cell bodies and processes. Similarly, VPA protects severe combined immunodeficient (SCID) mice against the neurodegeneration of HIV-1ADA infected monocyte-derived macrophages (MDMs). In SCID mice with HIV-1 MDM-induced encephalitis, VPA treatment significantly reduced neuronal phosphorylated β-catenin and tau without affecting HIV-1 replication or glial activation. We conclude that VPA protects neurons against HIV-1 infected MDM neurotoxicity, possibly through its effects on the phosphorylation of tau and β-catenin. The use of VPA as an adjuvant in treatment of human HAD is being pursued.

AB - Human immunodeficiency virus-1 (HIV-1) infection of the nervous system can result in neuroinflammatory events leading first to neuronal dysfunction then to cognitive and behavioral impairments in infected people. The multifaceted nature of the disease process, commonly called HIV-1-associated dementia (HAD), provides a number of adjunctive therapeutic opportunities. One proposed adjunctive therapy is sodium valproate (VPA), an anticonvulsant known to promote neurite outgrowth and increase β-catenin through inhibiting glycogen synthase kinase 3β activity and tau phosphorylation. We now show that VPA treatment of rat cortical neurons exposed to HIV-1 gp120 prevents resultant neurotoxic activities. This includes the induction of significant neurite outgrowth and microtubule-associated protein 2 (MAP-2) and neuron-specific nuclear protein (NeuN) antigens in affected neuronal cell bodies and processes. Similarly, VPA protects severe combined immunodeficient (SCID) mice against the neurodegeneration of HIV-1ADA infected monocyte-derived macrophages (MDMs). In SCID mice with HIV-1 MDM-induced encephalitis, VPA treatment significantly reduced neuronal phosphorylated β-catenin and tau without affecting HIV-1 replication or glial activation. We conclude that VPA protects neurons against HIV-1 infected MDM neurotoxicity, possibly through its effects on the phosphorylation of tau and β-catenin. The use of VPA as an adjuvant in treatment of human HAD is being pursued.

KW - HIV-1 associated dementia

KW - HIV-1 encephalitis

KW - Monocyte-derived macrophages

KW - Neuroprotection

KW - Severe combined immunodeficient mice

KW - Sodium valproate

UR - http://www.scopus.com/inward/record.url?scp=0141988725&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141988725&partnerID=8YFLogxK

M3 - Article

C2 - 14534250

AN - SCOPUS:0141988725

VL - 23

SP - 9162

EP - 9170

JO - Journal of Neuroscience

JF - Journal of Neuroscience

SN - 0270-6474

IS - 27

ER -